Oslo Heart Center, Division of Cardiovascular and Respiratory Medicine and Surgery, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
J Thorac Cardiovasc Surg. 2011 May;141(5):1145-9. doi: 10.1016/j.jtcvs.2010.07.003. Epub 2010 Aug 14.
Heparin coating of cardiopulmonary bypass circuits reduces the inflammatory response and increases the thromboresistance during extracorporeal circulation. These properties enables a lower systemic heparin dose, which has been shown to reduce the need for blood transfusions. Experience with this technique accumulated over 11 years has been analyzed.
All patients underwent on-pump coronary artery bypass grafting with heparin-coated circuits. Apart from some patients receiving a high intraoperative dose of aprotinin, the systemic heparin dose was reduced, with a lower level of an activated clotting time of 250 seconds during extracorporeal circulation. The overall strategy aimed at a fast-track regimen, with early extubation, minimal use of blood transfusions, and rapid postoperative recovery.
Altogether, 5954 patients were included; 1131 (19.0%) were female (median age, 70 years), and 4823 were male (median age, 65 years). The median additive EuroSCORE was 3 (range, 0-14; mean 3.5 ± 2.5). No significant signs of clotting were seen in any part of the extracorporeal circuit. Bank blood products were given to 427 (7.2%) patients. Median extubation time was 1.7 hours. The stroke rate was 1.0%, transient neurologic deficits occurred in 0.7%, and perioperative myocardial infarction occurred in 1.2%. On the fifth day, 88.1% of the patients were physically rehabilitated and ready for discharge. Thirty-day mortality was 0.9% (54 patients).
The experience with this patient cohort including mostly low- to medium-risk patients with a relatively short cardiopulmonary bypass time indicates that coronary artery bypass grafting performed with heparin-coated circuits and reduced level of systemic heparinization is safe and results in a very satisfactory clinical course. No signs of clotting or other technical incidents were recorded.
心肺转流过程中使用肝素涂层可减少炎症反应,增加体外循环的抗血栓性。这些特性使全身肝素剂量降低,从而减少输血需求。分析了 11 年来积累的这项技术经验。
所有患者均接受肝素涂层体外循环下的体外循环冠状动脉旁路移植术。除了一些患者术中接受高剂量抑肽酶外,全身肝素剂量减少,体外循环中激活凝血时间为 250 秒。整体策略旨在快速康复,包括早期拔管、尽量减少输血和快速术后恢复。
共纳入 5954 例患者,其中 1131 例(19.0%)为女性(中位数年龄为 70 岁),4823 例为男性(中位数年龄为 65 岁)。中位数附加 EuroSCORE 为 3(范围为 0-14;平均 3.5±2.5)。体外循环的任何部分均未见明显凝血迹象。向 427 例(7.2%)患者给予库存血制品。中位拔管时间为 1.7 小时。卒中发生率为 1.0%,短暂性神经功能缺损发生率为 0.7%,围手术期心肌梗死发生率为 1.2%。第 5 天,88.1%的患者身体康复,准备出院。30 天死亡率为 0.9%(54 例)。
该患者队列的经验包括大多数低至中危患者,体外循环时间相对较短,表明使用肝素涂层和降低全身肝素化水平的冠状动脉旁路移植术是安全的,临床效果非常满意。未记录到凝血或其他技术事件的迹象。